These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 11766415)

  • 1. HIV affinity hemodialysis as a treatment for AIDS.
    Tullis RH; Ambrus JA; Joyce JA
    Am Clin Lab; 2001; 20(9):22-3. PubMed ID: 11766415
    [No Abstract]   [Full Text] [Related]  

  • 2. Mathematical model of the effect of affinity hemodialysis on the T-cell depletion leading to AIDS.
    Tullis RH
    Blood Purif; 2004; 22(1):84-91. PubMed ID: 14732816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV infection in patients on dialysis and after renal transplantation.
    Heering P; Heinzler P; Bach D; Srampical B; Scheid A; Grabensee B
    Clin Nephrol; 1987 Apr; 27(4):212-3. PubMed ID: 3555910
    [No Abstract]   [Full Text] [Related]  

  • 4. [Aids: results with antibodies questionable].
    Paris KA
    Fortschr Med; 1992 Jun; 110(18):16. PubMed ID: 1644392
    [No Abstract]   [Full Text] [Related]  

  • 5. AIDS/HIV. A STEP into darkness or light?
    Moore JP; Klasse PJ; Dolan MJ; Ahuja SK
    Science; 2008 May; 320(5877):753-5. PubMed ID: 18467578
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunopathogenesis and immunotherapy in AIDS virus infections.
    Letvin NL; Walker BD
    Nat Med; 2003 Jul; 9(7):861-6. PubMed ID: 12835706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines. Monkey puzzles.
    Cohen J
    Science; 2002 Jun; 296(5577):2325-6. PubMed ID: 12089425
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of an oral therapeutic HIV-1 vaccine on AIDS patients with CD4 count above 250 cells/mm3.
    Jirathitikal V; Bourinbaiar AS
    Acta Virol; 2004; 48(2):73-8. PubMed ID: 15462281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS.
    Blattner WA; Oursler KA; Cleghorn F; Charurat M; Sill A; Bartholomew C; Jack N; O'Brien T; Edwards J; Tomaras G; Weinhold K; Greenberg M
    J Infect Dis; 2004 May; 189(10):1793-801. PubMed ID: 15122515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of newly emerging mutant viral disorders and role in bioterrorism.
    Ambrus JL; Ambrus JL; Ambrus CM
    Med Hypotheses; 2005; 64(6):1248-9. PubMed ID: 15823736
    [No Abstract]   [Full Text] [Related]  

  • 12. Is HIV-2-induced AIDS different from HIV-1-associated AIDS?
    Schim van der Loeff MF; Martinez-Steele E; Corrah T; Awasana AA; van der Sande M; Sarge-Njie R; McConkey S; Jaye A; Whittle H
    AIDS; 2008 Mar; 22(6):791-2. PubMed ID: 18356612
    [No Abstract]   [Full Text] [Related]  

  • 13. Affinity hemodialysis for antiviral therapy. II. Removal of HIV-1 viral proteins from cell culture supernatants and whole blood.
    Tullis RH; Duffin RP; Zech M; Ambrus JL
    Blood Purif; 2003; 21(1):58-63. PubMed ID: 12566663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of human immunodeficiency virus by high hydrostatic pressure.
    Nakagami T; Ohno H; Shigehisa T; Otake T; Mori H; Kawahata T; Morimoto M; Ueba N
    Transfusion; 1996 May; 36(5):475-6. PubMed ID: 8693517
    [No Abstract]   [Full Text] [Related]  

  • 15. Winning or losing: where are we in the fight against HIV and AIDS?
    Honey K
    J Clin Invest; 2007 Sep; 117(9):2348. PubMed ID: 17786227
    [No Abstract]   [Full Text] [Related]  

  • 16. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1.
    Deeks SG; Martin JN; Sinclair E; Harris J; Neilands TB; Maecker HT; Hagos E; Wrin T; Petropoulos CJ; Bredt B; McCune JM
    J Infect Dis; 2004 Jan; 189(2):312-21. PubMed ID: 14722897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Twenty-five years of HIV and AIDS: opportunities and challenges].
    Li TS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Oct; 28(5):605-8. PubMed ID: 17121214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of HIV-infections: success or crisis?].
    Pokrovskiĭ VV
    Ter Arkh; 2001; 73(11):52-4. PubMed ID: 11806206
    [No Abstract]   [Full Text] [Related]  

  • 19. The urological management of the patient with acquired immunodeficiency syndrome.
    Heyns CF; Fisher M
    BJU Int; 2005 Apr; 95(5):709-16. PubMed ID: 15784082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients.
    Ting PT; Koo JY
    Int J Dermatol; 2006 Jun; 45(6):689-92. PubMed ID: 16796629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.